WO2003070764A1 - Method for producing interferon - Google Patents
Method for producing interferon Download PDFInfo
- Publication number
- WO2003070764A1 WO2003070764A1 PCT/EP2003/001745 EP0301745W WO03070764A1 WO 2003070764 A1 WO2003070764 A1 WO 2003070764A1 EP 0301745 W EP0301745 W EP 0301745W WO 03070764 A1 WO03070764 A1 WO 03070764A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interferon
- alpha
- protein
- polypeptide
- residues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
Definitions
- the present invention relates generally to methods of producing interferon proteins comprising one or more cysteine residues and two or more polypeptide subunits, by chemical synthesis.
- the invention further relates to subunits constituting the interferon proteins and to their use in the production of biologically active interferon.
- Interferons are single-chain proteins released by cells invaded by viruses or certain other substances. Interferons are presently grouped into three major classes, designated leukocyte interferon (interferon-alpha, alpha- interferon, IFN-alpha, molecular weight 19kDa, approximately 165 amino acids), fibroblast interferon (interferon-beta, beta-interferon, IFN-beta, molecular weight 19KDa, approximately 165 residues) , and immune interferon (interferon-gamma, gamma-interferon, IFN-gamma, molecular weight 17kDa, approximately 140 residues).
- leukocyte interferon interferon-alpha, alpha- interferon, IFN-alpha, molecular weight 19kDa, approximately 165 amino acids
- fibroblast interferon interferon-beta, beta-interferon, IFN-beta, molecular weight 19KDa, approximately 165 residues
- IFN-betas contain one disulfide bond, and IFN-gammas have no disulfides. These disulfide bonds are formed by oxidation of the side-chains of cysteine residues.
- the amino acid sequence of mature recombinant IFN-alpha A contains cysteine residues at positions 1, 29, 98 and 138.
- Intramolecular disulfide bonds are formed between the cysteine residues at positions 1 and 98, and between the cysteine residues at positions 29 and 138.
- Interferons have a variety of biological activities, including antiviral, immunoregulatory and antiproliferative properties, and are, therefore, of great interest as therapeutic agents in the control of cancer and various viral diseases, notably Hepatitis C and Hepatitis B.
- Current commercial methods for the production of interferon involve the synthesis of recombinant proteins in bacterial or mammalian cells.
- interferon-alpha is produced by harvesting bacteria containing a plasmid encoded with the gene for the interferon-alpha protein, e.g.
- interferon-alpha is present in reduced form and contaminated with many other proteins.
- This crude mixture is subjected to conditions to oxidize the cysteine residues to form the two specific disulfide bonds essential for biological activity.
- This mixture of native interferon, mis-folded interferon and the other contents of the cell lysate are then subjected to a series of purification techniques to obtain purified interferon.
- Staehelin et al . J. Biol . Chem. , 256, 9750-9754 (1981) described the preparation of recombinant interferon- alpha from E. coli and the purification of the cell lysates using immunoaffinity column chromatography where the column resin is derivatized with a specific antibody that binds the interferon-alpha. While the immunoaffinity column used in the Staehelin method selectively binds the interferon-alpha, the cost of immunoaffinity columns is high and the useful life of the column is limited.
- interferon-alpha A particularly difficult contaminant from the recombinant production of interferon-alpha is the interferon- alpha product comprising an added methionine at the N- terminus .
- This contaminant is difficult to remove during purification because it is so similar to interferon-alpha in charge, size and tertiary structure.
- Hochuli (1986) was only able to remove this contaminant by using immunoaffinity chromatography and three additional purification steps.
- the use of immunoaffinity columns to purify the recombinant interferon-alpha introduces the risk of contamination by viruses or by murine immunogobulin in the final product.
- SPPS Solid Phase Peptide Synthesis
- RP-HPLC reversed-phase HPLC
- Boc t-butyloxycarbonyl, Kent, 1988
- Fmoc 9- fluorenyloxycarbonyl, Fields and Noble, 1990
- reaction yields are less than 100% and the unreacted species accumulate on the resin.
- to synthesize a peptide of 50 residues requires 100 reactive steps of very high yield. Even if the efficiency of each step was 99% then effectively none of the target peptide would be obtained.
- the final cleavage step which also removes the side- chain protecting groups can generate species which can modify the target peptide.
- the desired peptide is initially obtained contaminated by shorter peptides (deletion or truncation sequences), some of which have physicochemical properties (size, charge, hydrophobicity) very similar to that of the target peptide and from which it can be very difficult to obtain the desired peptide in pure form.
- shorter peptides evolution or truncation sequences
- physicochemical properties size, charge, hydrophobicity
- the polypeptide sequence becomes longer, it tends to be increasingly difficult to both synthesize and purify the desired sequence to obtain it in practical quantities. It is generally accepted that the synthesis of polypeptides longer than about 50 amino acids, though possible, is far from routine (see e.g. Kochendoerfer and Kent, Curr . Opin. Chem.
- the native chemical ligation reaction is carried out to ligate a first peptide, of which the N-terminal residue is a Cys with a reduced sulfhydryl moiety, with a second peptide, in which the alpha-carboxylate has been converted to a thioester.
- a second peptide in which the alpha-carboxylate has been converted to a thioester.
- the peptide-C-alpha-thioester can react chemoselectively with the N-terminal Cys on the second peptide to form a side-chain thioester-linked intermediate. This spontaneously undergoes intermolecular rearrangement to form a native peptide bond at the ligation site, and to regenerate the sulfhydryl group of the Cys side-chain.
- auxiliary groups have been disclosed. These bear ⁇ -amino thiols, e.g. Low et al . , Proc. Natl. Acad. Sci. USA, 98, 6554, (2001), Kawakami et al . Org. Lett. 3: 1403 (2001) or g-amino thiols, e.g. Canne et al . , J. Am. Chem. Soc. 118, 5891 (1996).
- the auxiliary comprises a moiety allowing cleavage of the auxiliary from the peptide, e.g. by strong acid.
- polypeptides prepared by this technique are typically 70-110 residues long (e.g. SDFaN33A (68 residues), Ueda et al . , J. Biol. Chem. 272, 24966 (1997), Eglin C (70 residues), W.-Y. Lu et al . , Biochem. 39, 3575 (2000) and barnase (110 residues), US-6, 184, 344 ) .
- the longest polypeptide that has been demonstrated to have been prepared in high purity by native chemical ligation is human type II secretory phospholipase A2 (124 residues) (Hackeng et al . Proc.
- the protecting group used was the acetomidomethyl group, Acm (Veber et al . , J. Am. Chem. Soc. 94: 5456 (1972)) or the methylsulfonyl ethyloxycarbonyl (Tesser et al . , Int. J. Peptide Protein Res., 7 : 295 (1975)) .
- Removal of the Acm group requires treatment of peptides with mercury salts, often under strongly acidic conditions, and subsequently with ⁇ -mercaptoethanol . These conditions risk modification of the polypeptide, e.g. Asp-Gly sequences may be sensitive to strong acid, which can cleave the peptide backbone. Careful purification is required to ensure that all mercury is removed from the polypeptide.
- the Msc group is removed under strongly basic conditions which can also modify polypeptides, e.g. dehydration of Asn residues.
- the mixture On completion of the first native ligation reaction the mixture is purified, the N-terminal Cys of the ligated peptide is then deprotected and the mixture is purified.
- the product of the first ligation then takes part in another native chemical ligation with a third peptide which has a thioester group. This process is repeated to assemble the entire sequence of the polypeptide.
- This allows even longer polypeptides to be prepared in high purity.
- the examples that have been disclosed are of similar length as those produced by native ligation of two fragments, e.g. three-step, four-fragment synthesis of human secretory phospholipase A2 (124 residues) (Hackeng et al . (1999)).
- a disadvantage of the sequential ligation technique is that the additional purification steps necessary make this time-consuming, labor-intensive and therefore costly as a method of production.
- Methods to accelerate this sequential ligation by assembling the ligated fragments on a polymeric resin have been disclosed by Canne et al . , 1999, who synthesized the 118 residue human group V secretory phospholipase A2 by this method.
- Solid-Phase Protein Ligation approach is that non-standard linkers must be prepared and used to add the purified C- terminal fragment to the resin on which the fragments are assembled by native ligation.
- Native ligation relies on two key steps. One is the ligation step to join the two peptides. The second is the preparation of a peptide-alpha-thioester .
- the peptide thioester was synthesized on a resin with a linker that, on cleavage of the peptide, yielded a peptide thioacid. This thioacid group was subsequently transformed into a thioester in solution.
- Linkers have since been disclosed that afford peptide-alpha- thioesters directly on cleavage (e.g. hackeng et al . (1999)). These linkers are only useful if the stepwise assembly of the peptides is by the Boc method. Although useful for the rapid synthesis of medium length peptides, the Boc method is less efficient in the synthesis of longer peptides . In fact it has been noted that for native chemical ligation, the process requires use of fairly pure peptides, limiting the length of precursor fragments employed in each ligation step to 30-35 residues (see Villain et al . (2001)). In addition, to obtain peptides in reasonable purity by Boc chemistry the cleavage of the peptide from the resin must be done by HF, which is highly toxic.
- the other main method of SPPS uses basic conditions for the repetitive removal of the N-alpha- protecting group (Fmoc) .
- Thioesters are not stable to these conditions, and although peptide thioesters from 10 residues to 25 residues have been synthesized by the Fmoc method (see Clippingdale et al. (2000), Li et al . (1998), modified linkers and non-standard Fmoc-deprotection conditions had to be used. Even so, considerable loss of material by premature cleavage of peptide from the resin during Fmoc deprotection makes these resins impracticable for synthesizing longer peptide thioesters.
- interferon- alphas have four Cys residues, at positions 1, 29, 98 and 137.
- To synthesize these proteins by one step of native ligation would require the synthesis of a peptide-thioester of 97 amino acids and a peptide of 68 residues.
- Alternative sites or native ligation would require syntheses of either a peptide thioester or a peptide acid with 137 amino acids, which would be even more difficult to make in practical yield and purity.
- the present invention provides improved methods for the production of interferon proteins, comprising one or more cysteine residues and two or more polypeptide subunits, which method comprises the steps of: (a) synthesizing a first polypeptide subunit of said interferon protein having a Cys, or a ligation auxiliary, as the N-terminal residue by solid-phase peptide synthesis and purifying said subunit; (b) synthesizing at least one additional polypeptide subunit of said interferon protein having a protected Cys or protected auxiliary at the N-terminal and an alpha- carboxylate thioester at the C-terminal by solid-phase peptide synthesis and purifying said additional subunit (s); (c) ligating said first polypeptide subunit and said additional subunit (s) by native chemical ligation to produce a full-length interferon polypeptide;
- interferon proteins may be synthesized in high purity and biological activity by chemical synthesis. This method has the advantages of avoiding the problems of N-terminal Met, or contamination with other proteins, murine immunoglobulins or cellular nucleic acids, all potential risks with interferons produced by recombinant means.
- interferon proteins of high purity and with full biological activity are obtained in one purification step by reverse- phase HPLC following refolding and disulfide bridge formation .
- long polypeptide fragments of the interferon proteins may be synthesized as C-alpha-thioesters in the high purity necessary for native ligation.
- the biologically active interferon protein is selected from the group consisting of an alpha-interferon protein, a beta- interferon protein, and a gamma-interferon protein.
- Particularly preferred interferon proteins are interferon alpha2a protein, interferon alpha2b protein, interferon alpha2c protein, synferon, interferon alpha-nl protein, interferon alpha-n2 protein, and interferon alpha-n3 protein.
- the polypeptide subunits are preferably purified using a column chromatography technique with reverse phase column chromatography being preferred.
- polypeptide subunits may be synthesized by various means known in the art but are preferably produced according to the solid phase synthetic method wherein the N- alpha protective moiety is 9-fluorenylmethyloxycarbonyl (Fmoc) .
- the interferon sequence is broken down according to potential sites of ligation, with ligation capable at any cysteine residue.
- interferon-alpha has four cysteine residues at position 1, 29, 98 and 138.
- these four cysteine residues leave open the possibility of linking as many as four separate portions of full length protein 1-28, 29-97, 98-137, and 138-165 to form the full length interferon-alpha .
- Interferon-alpha subunits 1-97 and 98-165 were prepared using conventional solid phase chemistry, cleaved from the resin, ligated together, deprotected and then oxidized to form pure, full length Interferon-alpha protein.
- interferon-alpha subunits 1-28, 29-97 and 98-165 were prepared using conventional solid phase chemistry, cleaved from the resin and purified. Fragments 29-97 and 98- 165 were ligated together, the N-terminal was deprotected and the resulting fragment 29-165 was ligated with fragment 1-28, Cysl was deprotected and the full-length interferon-alpha was purified. The interferon-alpha was refolded and the Cys residues were oxidized to form the interferon-alpha native which was isolated from the refolding mixture to afford the biologically active protein.
- interferon-alpha subunits 1-28, 29-97, 98-137 and 138-165 were prepared using conventional solid phase chemistry, cleaved from the resin and purified after which the fragments are ligated together, the N-terminal deprotected and the full-length interferon-alpha purified.
- the interferon-alpha was refolded and the Cys residues were oxidized to form the interferon-alpha native which was isolated from the refolding mixture to afford the biologically active protein.
- interferon-alpha subunits 1-97, 98-137 and 138-165 are prepared using conventional solid phase chemistry, cleaved from the resin and purified after which the fragments are ligated together, the N-terminal deprotected and the full-length interferon-alpha purified.
- the interferon-alpha isrefolded and the Cys residues are oxidized to form the interferon-alpha native which is isolated from the refolding mixture to afford the biologically active protein.
- Figure 5 Amino acid sequence of human interferon- alpha2b. Disulfide bonds are formed between Cysl and Cys 98, and between Cys29 and Cysl38.
- the present invention provides a solution to the problems of chemical synthesis of alpha-interferons which present a challenge to the art by virtue of their complexity and size.
- the present invention relates to the production of interferon proteins by use of solid phase peptide synthesis coupled with the native chemical ligation of sections of an interferon protein to form the full length protein.
- the target interferon protein is synthesized by utilizing the cysteine residues that are present in the interferon protein.
- Each cysteine residue present in the target interferon protein is a potential site of ligation, where two sections of the full length protein can be brought together to make a larger section of the full length interferon protein. This stepwise ligation of sections of the interferon protein will eventually lead to the formation of the full length interferon protein.
- the first step in the method comprises the synthesis of a first section of a full length interferon protein by standard solid phase peptide synthesis (SPPS) .
- SPPS solid phase peptide synthesis
- the synthesis of the first section of the full length protein is complete when the peptide is elongated to a Cys residue, the chain elongation being made from the C-terminus to the N- terminus .
- the section is cleaved from the resin and purified using standard column chromatography techniques, including reverse phase column chromatography.
- the second polypeptide is then synthesized on a resin from which it may be cleaved to form a peptide thioester, for example according to the procedure of Ingenito et al. (1999) .
- the polypeptide is elongated on this resin by SPPS from the position preceding the cysteine residue at the N-terminal of the first polypeptide to another Cys.
- This second Cys bears a protecting group that is stable to the conditions used to remove the protecting groups from the side chains of the other residues, including other Cys in this peptide.
- the second section is purified using standard column chromatography techniques, including reverse phase column chromatography.
- the first and second sections of the target interferon protein are ligated together. This step is for example accomplished using the ligation technique developed by Dawson et al . (1994).
- the N-terminal Cys of the product from the ligation reaction is then deprotected and the fully deprotected product is purified using column chromatography, including reverse phase column chromatography .
- This sequence of synthesis on the solid phase, followed by ligation can form the full length interferon protein in only one step of ligation or it can be performed numerous times until the full length protein is formed.
- the tertiary structure of the interferon protein is allowed to be properly developed, and the cysteines are oxidized to form disulfide bonds.
- the biologically active IFN is then isolated by column chromatography.
- the interferon protein is an interferon-alpha. It is a particularly preferred embodiment of the invention that the interferon protein is an interferon-alpha selected from the group of IFN-alpha2a, IFN-alpha2b, IFN-alpha2c and Synferon.
- the full-length interferon-alpha is assembled by ligating two peptide fragments comprising IFN-alpha ( 98-165) , having a reduced Cys as the N-terminal residue, with the alpha carboxylate thioester of IFN-alpha (1-97) , bearing a protected Cys at the N-terminal .
- the full- length interferon is assembled by two ligations of three peptide fragments comprising IFN-alpha (1-28 ) , IFN-alpha (29- 97) and IFN-alpha (98-165) .
- the fragments comprising IFN-alpha ( 98-165) and IFN-alpha (29-97) are first ligated and purified to form IFN-alpha (29-165) , then a second ligation is made between IFN-alpha (1-28) and IFN-alpha (29- 165) to form IFN-alpha (1-165) .
- the three fragments are IFN-alpha (1-97) , IFN-alpha (98-137 ) and IFN- alpha (138-165) .
- the full- length interferon is assembled by three ligations of four peptide fragments comprising IFN-alpha (1-28 ) , IFN-alpha (29- 97), IFN-alpha (98-137) and IFN-alpha (138-165) .
- the polypeptide fragments are synthesized by the method of solid phase peptide synthesis (SPPS) . It is particularly preferred that the polypeptide fragments are synthesized by Fmoc SPPS.
- the group used to protect the N-terminal Cys of the additional polypeptide fragments is selected from the acetomidomethyl (Acm) group, the methylsulfonylethyloxycarbonyl group (Msc) or the thiazolidine-4-carboxylate residue (Thz) . It is a preferred embodiment of the invention that the polypeptides are isolated by reverse phase HPLC.
- the full length, fully deprotected interferon protein is refolded and oxidized by (a) dissolving the fully deprotected interferon in an aqueous buffer solution with a concentration of a guanidinium salt sufficient to dissolve the interferon polypeptide; (b) diluting the said aqueous buffer solution with another solution containing a redox couple so that the final concentration of the guanidinium salt is 1.5M or less and the final pH is in the range 5 to 8; and (c) incubating said aqueous buffer solution at a temperature of 20-25°C.
- the redox couple is selected from the group of oxidized and reduced glutathione, cysteine and cystine, and oxidized and reduced cysteamine.
- the refolded and oxidized interferon protein is isolated as biologically active protein by reverse phase HPLC and lyophilization .
- the invention furthermore relates to interferon polypeptide subunit selected from the group consisting of polypeptides comprising the residues 1-28, 29-97, 98-137, 138-165, 1-97, 98-165 of interferon-alpha and to the use of consecutive polypeptide subunits selected from the above group for the production of interferon-alpha.
- human interferon-alpha2b was produced according to the method wherein two interferon- alpha subunit polypeptides were prepared by solid-phase peptide synthesis.
- the approach taken in this Example was the synthesis of two large sections of the full length interferon-alpha protein, wherein after one ligation reaction the full length human interferon-alpha protein was formed.
- a polypeptide comprising amino acids 1-97 of human interferon-alpha was synthesized using Fmoc-SPPS.
- the other segment of interferon-alpha, from position 98-165, was also prepared using Fmoc-SPPS.
- cysteine residue at the 98 position of interferon-alpha was utilized to ligate the two sections together to form the full length human interferon-alpha, which was then allowed to reform the native, biologically active structure and the native disulfide bonds and isolated.
- Interferon-alpha (98-165) comprises a 68 amino acid section of human interferon-alpha from position 98 to position 165 in the amino acid sequence of interferon-alpha holoprotein.
- Interferon-alpha (98-165) was prepared by solid- phase peptide synthesis (SPPS) on Fmoc-Glu (OtBu) -Novasyn ® TGA resin, initial loading 0.13mmol/g, on a scale of 0.08 mmol.
- Peptide was cleaved from the resin (0.67g of peptide- resin, one half of the synthesis) with a mixture of TFA- triisopropylsilane-water-phenol-ammonium iodide (21 ml, 3 ml, 1.25 ml, 1.25 g, 0.40 g) for 3 hours.
- the resin was removed by filtration and the peptide was precipitated by addition of the cleavage solution to cold methyl t-butyl ether (3 tubes of 35 ml) .
- the precipitate was pelleted by centrifugation and washed three times with cold methyl t-butyl ether (2 x 30 ml and 1 x 20 ml per tube) .
- Interferon-alpha ( 1-97 ) Cysl (Acm) ethyl-3-mercapto- propionate thioster comprises the first 97 amino acids of human interferon-alpha2b (Fig. 5; SEQ ID NO: 1) wherein the terminal carboxyl group at position 97 has been converted to an ethyl-3-mercaptopropionate thioester.
- the C-terminal amino acid, Ala was coupled to 4-sulfamylbutyryl AM resin (Novabiochem) by the method of Backes and Ellman (1999) .
- Fmoc-Ala-OH (6.0 g) and ethyldiisopropylethylamine (6.2 ml) were added to a suspension of 4-sulfamylbutyryl AM resin (3.28 g, initial loading 1.12 mmol/g) in chloroform (35 ml).
- PyBOP ® (1.56 g) and chloroform (5 ml) were added and stirring was continued at -18 °C for 1.5 hours.
- the resin was filtered and washed with chloroform, isopropanol and dried under high vacuum. Unreacted sulfonamide groups were capped with a solution of di-t-butyl dicarbonate (1.5 g) and ethyldiisopropylamine (2.4 ml) in dichloromethane (DCM, 2 x 15 min) . After each capping the resin was washed with dichloromethane and after the second it was dried under high vacuum. The loading of Fmoc-Ala was measured as 0.38mmol/g using the method described in the Novabiochem 2000 Catalogue for Solid Phase Peptide Synthesis, page P4. This resin was used as the starting resin for the solid-phase synthesis on a scale of 0.1 mmol.
- Protocols and reagents were the same as for the synthesis of interferon-alpha2b (98-165) , with the following exceptions. Ser68-Thr69 and Ile24-Ser25 were coupled as the pseudoproline dipeptides. Half of the resin was removed from the reaction vessel after the coupling of Lys31. The synthesis was continued and the final residue was coupled as Fmoc-Cys (Acm) , Fmoc-deprotected and reprotected with the Boc group as described above. The resin was washed and dried under high vacuum, weight 0.37 g.
- Interferon-alpha2b (1-97 ) -cysl (Acm) ethyl-3- mercaptopropionate thioester was obtained in 96% purity by analytical HPLC, 2.8 mg.
- interferon-alpha2b-Cysl The ligation reaction proceeded with the reaction of near equi-molar amounts of the interferon-alpha (1- 97) Cysl (Acm) ethyl-3mercaptopropionate thioester and interferon-alpha (98-165) .
- Interferon-alpha2bCysl (Acm) , 1.07 mg, was dissolved in 0.2 ml of 50% acetic acid-water. A solution of 0.8 mg of mercuric acetate in 15 ⁇ l of 50% acetic acid-water was added and the solution was sparged with argon. The solution was agitated gently for 6 hours. ⁇ -Mercaptoethanol (18 ⁇ l) was added and the solution was agitated for a further 23 hours.
- the mixture was centrifuged and the supernatant was purified by RP-HPLC on a Vydac C18 column (238TP54), eluting with a linear gradient of acetonitrile-0.1% TFA in water-0.1% TFA, controlled by a Waters Alliance system.
- the purification was monitored by UV at 214nm and fractions of the major peak were analyzed by MALDI-MS. Those fractions containing the desired peptide were combined and lyophilized to afford 0.81 mg.
- the synthetic interferon-alpha was allowed to fold into the biologically active interferon-alpha2b in an oxidative buffer comprising glutathione oxidized: reduced in a ratio of 1:2.
- 0.34 mg of deprotected interferon-alpha2b from paragraph 6 was dissolved in 0.22 ml of buffer A (0.1M Tris, 6M GdmCl, ImM EDTA sodium salt, pH 7.5) that had been sparged with argon.
- This solution was diluted with 30 ml each of solutions of oxidized glutathione and of reduced glutahione, each solution containing 0.3 mg of glutathione in 30 ⁇ l of buffer B (0.1M Tris, 1 mM EDTA sodium salt, pH 7.5), and with 0.66 ml of buffer B.
- buffer B 0.1M Tris, 1 mM EDTA sodium salt, pH 7.5
- Samples were removed for analysis by RP-HPLC at the start of the folding and after 22 hours. The elution time of the main peak changed from 40.2 minutes at the start to 36.3 minutes after 22 hours, consistent with folding of the protein. After 22 hours the folding mixture was centrifuged at 13000 rpm for 1 min.
- MALDI-MS of this sample showed that a peptide with the expected mass was present and an NEM test for free Cys residues (Mant et al . (1997)) was negative, confirming that both disulfide bonds had formed. The purity was 95% by analytical HPLC.
- interferon-alpha2b prepared in paragraph 7 was diluted by 1 x 10 4 with DMEM and added to bovine MDBK cells (0.18 ml interferon-alpha was added to 0.15 ml of cells at 5 x 10 4 cells /ml) in a 96-well plate. Aliquots of interferon added to each well were a third of the concentration of the interferon in the previous well. After 24 hours the cells were challenged with VSV. 24 hours after challenge the cells were examined by microscope and the well in which 50% of cells survived was taken as having a concentration of one unit of interferon/ml . The activity of interferon-alpha2b measured by this test was calculated to be 2.5 ⁇ 0.8 x 10 7 U/ mg.
- Interferon-alpha2b (29-97 )Cys29Thz ethyl-3- mercaptopropionate thioester comprises the amino acids 29-97 of human interferon-alpha2b wherein the terminal carboxyl group at position 97 has been converted to an ethyl-3- mercaptopropionate thioester and the cysteine residue at position 29 has been incorporated as the (L) -thiazolidine-4- carboxylic acid (Thz) residue.
- the C-terminal amino acid, Ala was coupled to 4-sulfamylbutyryl AM resin (Novabiochem) by the method of Backes and Ellman (1999) as described for the synthesis of interferon-alpha2b (1-97 ) Cysl (Acm) ethyl-3- mercaptopropionate thioester in Example 1.
- This resin was used as the starting resin for the solid-phase synthesis on a scale of 0.1 mmol.
- the peptide interferon-alpha2b (29-97 ) Cys29Thz ethyl- 3-mercaptopropionate thioester was cleaved from the resin using the method of Ingenito et al . (1999) .
- a flame- dried, 100ml round bottom flask was charged with argon and Boc-protected peptide resin (0.50 g) and anhydrous tetrahydrofuran (THF, 7 ml) were added. After 10 min trimethylsilydiazomethane (7 ml, 2M solution in hexanes) was added and the mixture was stirred at ambient temperature for 2 hours.
- the resin was separated by filtration and washed with THF and DCM.
- CyslThz ethyl-3-mercapto- propionate thioester comprises the first 28 amino acids of human interferon-alpha2b wherein the terminal carboxyl group at position 28 has been converted to an ethyl-3- mercaptopropionate thioester.
- the C-terminal amino acid, Ser was coupled to 4-sulfamylbutyryl AM resin (Novabiochem) by the method of Backes and Ellman (1999).
- Fmoc-Ser (tBu) - OH (4.17 g) and ethyldiisopropylethylamine (3.7 ml) were added to a suspension of 4-sulfamylbutyryl AM resin (1.95 g, initial loading 1.12 mmol/g) in chloroform (20 ml).
- the mixture was cooled to -20°C, PyBOP ® (5.67g) was added and stirring was continued at -20 °C for 3.5 hours.
- the resin was filtered and washed with chloroform.
- Protocols and reagents were the same as for the synthesis of interferon-alpha (98-165) with the following exceptions.
- Ile24-Ser25 were coupled as the c-pseudoproline dipeptides.
- the residues Argl2, Argl3, Thrl4, Leul5, Metl6, Leul7, Leul8, Alal9, Arg22 and Arg23 were all double-coupled.
- Cys29 was incorporated as B (L) -thiazolidine-4-carboxylic acid (Thz) .
- the synthesis was finished at CyslThz by coupling the final residue as Boc-Thz-OH.
- the resin was washed and dried under high vacuum, weight 0.37 g.
- the ligation reaction proceeded with the reaction of a near equi-molar amounts of the interferon-alpha2b (29- 97)Cys29Thz ethyl-3-mercaptopropionate thioester and interferon-alpha2b (98-165) .
- dithiothreitol (DTT, 0.37 g) was added as a solution in 3 ml of 6M guanidinium chloride, 0. IM sodium phosphate pH 7.5 and the ligation mixture was incubated for a further 2 hours at 37 °C.
- the solution was diluted with 3 ml acetonitrile and 2 ml 6M guanidinium chloride, 0. IM sodium phosphate pH 7.5 and purified by RP-HPLC on a Vydac C8 column (208TP510) with a linear gradient of acetonitrile-0.1% TFA in water-0.1% TFA, controlled by a Waters semi-prep HPLC system. The purification was monitored by UV at 214 nm. Fractions were analysed by MALDI-MS and those containing the target polypeptide were combined and lyophilized to afford 4.7 mg, purity 97% by analytical HPLC.
- the N-terminal Cys of interferon-alpha2b (29- 165)Cys29Thz was regenerated by treatment with O-methyl- hydroxylamine hydrochloride at pH 4.0.
- Interferon-alpha2b (29- 165)Cys29Thz (4.6mg) was dissolved in 6M guanidinium hydrochloride, 0.3M O-methylhydroxylamine hydrochloride, 0. IM acetic acid adjusted to pH 4.0 with sodium hydroxide. After 0.5 hours at 22-24 °C the solution was incubated at 37 °C. The solution was desalted on a Hi-TrapTM column (Pharmacia) , controlled by a KTa FPLC, eluting with 6M guanidinium chloride 0. IM sodium phosphate pH 7.0.
- the ligation reaction proceeded with the reaction of near equimolar amounts of the interferon-alpha2b (29- 97)Cys29Thz ethyl-3mercaptopropionate thioester and interferon-alpha2b (98-165) .
- interferon-alpha2b was allowed to fold into the biologically active interferon-alpha.
- interferon-alpha2b (0.88 mg) was dissolved in 0.5 ml of buffer A (0.1M Tris, 6M Gd Cl, InM EDTA sodium salt, pH 8.0) that had been sparged with argon.
- buffer A 0.1M Tris, 6M Gd Cl, InM EDTA sodium salt, pH 8.0
- This solution was diluted with 61 ⁇ l each of solutions of oxidized glutathione and of reduced glutahione, each solution containing 0.61 mg of glutathione in 61 ⁇ l of buffer B (0.1M Tris, 1 mM EDTA sodium salt, pH 8.0), and with 1.5 ml of buffer B.
- the solution was mixed and allowed to stand at room temperature (22 °C) .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003569671A JP2005532267A (en) | 2002-02-19 | 2003-02-19 | Method for producing interferon |
KR10-2004-7012859A KR20040095223A (en) | 2002-02-19 | 2003-02-19 | Method for producing interferon |
EP03709716A EP1476465A1 (en) | 2002-02-19 | 2003-02-19 | Method for producing interferon |
CA002473078A CA2473078A1 (en) | 2002-02-19 | 2003-02-19 | Method for producing interferon |
AU2003214068A AU2003214068A1 (en) | 2002-02-19 | 2003-02-19 | Method for producing interferon |
NO20043935A NO20043935L (en) | 2002-02-19 | 2004-09-20 | Process for the preparation of interferon |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02075722.5 | 2002-02-19 | ||
EP02075722 | 2002-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003070764A1 true WO2003070764A1 (en) | 2003-08-28 |
Family
ID=27741191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/001745 WO2003070764A1 (en) | 2002-02-19 | 2003-02-19 | Method for producing interferon |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1476465A1 (en) |
JP (1) | JP2005532267A (en) |
KR (1) | KR20040095223A (en) |
AU (1) | AU2003214068A1 (en) |
CA (1) | CA2473078A1 (en) |
NO (1) | NO20043935L (en) |
PL (1) | PL372298A1 (en) |
WO (1) | WO2003070764A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007049635A1 (en) * | 2005-10-25 | 2007-05-03 | Riken | Process for production of peptide thioester |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6174361B2 (en) * | 2013-04-19 | 2017-08-02 | 株式会社日立製作所 | Method for producing protein-immobilized carrier |
CN110461861A (en) * | 2016-11-09 | 2019-11-15 | 南洋理工大学 | The preparation and utilization of ginseng peptide peptide similar with ginseng peptide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996034878A1 (en) * | 1995-05-04 | 1996-11-07 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
-
2003
- 2003-02-19 CA CA002473078A patent/CA2473078A1/en not_active Abandoned
- 2003-02-19 JP JP2003569671A patent/JP2005532267A/en active Pending
- 2003-02-19 AU AU2003214068A patent/AU2003214068A1/en not_active Abandoned
- 2003-02-19 KR KR10-2004-7012859A patent/KR20040095223A/en not_active Application Discontinuation
- 2003-02-19 PL PL03372298A patent/PL372298A1/en unknown
- 2003-02-19 EP EP03709716A patent/EP1476465A1/en not_active Withdrawn
- 2003-02-19 WO PCT/EP2003/001745 patent/WO2003070764A1/en not_active Application Discontinuation
-
2004
- 2004-09-20 NO NO20043935A patent/NO20043935L/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996034878A1 (en) * | 1995-05-04 | 1996-11-07 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
Non-Patent Citations (3)
Title |
---|
CANNE L E ET AL: "EXTENDING THE APPLICABILITY OF NATIVE CHEMICAL LIGATION", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 118, no. 25, 26 June 1996 (1996-06-26), pages 5891 - 5896, XP002064668, ISSN: 0002-7863 * |
HACKENG T M ET AL: "Protein synthesis by native chemical ligation: Expanded scope by using straightforward methodology", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, August 1999 (1999-08-01), pages 10068 - 10073, XP002165723, ISSN: 0027-8424 * |
LOW DONALD W ET AL: "Total synthesis of cytochrome b562 by native chemical ligation using a removable auxiliary.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 12, 5 June 2001 (2001-06-05), June 5, 2001, pages 6554 - 6559, XP002241361, ISSN: 0027-8424 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007049635A1 (en) * | 2005-10-25 | 2007-05-03 | Riken | Process for production of peptide thioester |
US8076299B2 (en) * | 2005-10-25 | 2011-12-13 | Riken | Method for producing peptide thioester |
JP5014148B2 (en) * | 2005-10-25 | 2012-08-29 | 独立行政法人理化学研究所 | Method for producing peptide thioester |
Also Published As
Publication number | Publication date |
---|---|
NO20043935L (en) | 2004-09-20 |
EP1476465A1 (en) | 2004-11-17 |
JP2005532267A (en) | 2005-10-27 |
KR20040095223A (en) | 2004-11-12 |
AU2003214068A1 (en) | 2003-09-09 |
PL372298A1 (en) | 2005-07-11 |
CA2473078A1 (en) | 2003-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Canne et al. | Total chemical synthesis of a unique transcription factor-related protein: cMyc-Max | |
Clippingdale et al. | Peptide thioester preparation by Fmoc solid phase peptide synthesis for use in native chemical ligation | |
RU2275377C2 (en) | Method for space packing chemically synthesized polypeptides | |
Tam et al. | Disulfide bond formation in peptides by dimethyl sulfoxide. Scope and applications | |
JP3863579B2 (en) | Method for obtaining insulin with correctly linked cystine bridges | |
EP1392718B1 (en) | Improved native chemical ligation with three or more components | |
Aimoto | Contemporary methods for peptide and protein synthesis | |
Moroder et al. | Insulin—from its discovery to the industrial synthesis of modern insulin analogues | |
CN111670194B (en) | Preparation of glucagon peptides | |
Hojo et al. | Application of a novel thioesterification reaction to the synthesis of chemokine CCL27 by the modified thioester method | |
JP5328345B2 (en) | Method for producing peptide thioester compound | |
Shigenaga et al. | Sequential native chemical ligation utilizing peptide thioacids derived from newly developed Fmoc-based synthetic method | |
US20220033440A1 (en) | An improved process for the preparation of plecanatide | |
JPH10152500A (en) | Synthesis of peptide in solid phase | |
WO2003070764A1 (en) | Method for producing interferon | |
JP6010052B2 (en) | Method for preparing a peptide by assembling a plurality of peptide fragments | |
Bhargava et al. | Synthesis of a cyclic analog of oxidized glutathione by an intersite reaction in a swollen polymer network | |
Atherton et al. | Peptide synthesis. Part 6. Protection of the sulphydryl group of cysteine in solid-phase synthesis using N α-fluorenylmethoxycarbonylamino acids. Linear oxytocin derivatives | |
Kitagawa et al. | Total chemical synthesis of large CCK isoforms using a thioester segment condensation approach | |
EP3875466A1 (en) | Process for the synthesis of etelcalcetide | |
FUJII et al. | Studies on Peptides. CLVI. Synthesis of Second Human Calcitonin Gene-Related Peptide (β-hCGRP) by Application of a New Disulfide-Bonding Reaction with Thallium (III) Trifluoroacetate | |
CN114945580B (en) | Method for synthesizing south Ji Botai | |
Giesler | Better, Faster, Stronger: Improving Chemical Protein Synthesis | |
Sapia et al. | Evaluation of two new coupling agents for incorporation of α, α-dialkylamino acids, such as α-methylalanine, in solid-phase peptide synthesis | |
Wucherpfennig | Chemical protein synthesis by α-ketoacid-hydroxylamine ligation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003709716 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200405650 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003214068 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2473078 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 163353 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1804/CHENP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 534773 Country of ref document: NZ Ref document number: 20038041030 Country of ref document: CN Ref document number: 1020047012859 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003569671 Country of ref document: JP Ref document number: 372298 Country of ref document: PL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004127938 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2003709716 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003709716 Country of ref document: EP |